Worth Watching Stocks: Approach Resources, Inc. (NASDAQ:AREX), The Buckle, Inc. (NYSE:BKE), Osiris Therapeutics, Inc. (NASDAQ:OSIR), Destination XL Group, Inc. (NASDAQ:DXLG),

Approach Resources, Inc. (NASDAQ:AREX) reported Net loss for 2015 was $174.1 million, or $4.30 per diluted share, on revenues of $131.3 million. Net loss for 2015 included an unrealized loss on commodity derivatives of $33.2 million, a realized gain on commodity derivatives of $52.5 million, impairment expense of $220.2 million, rig termination fees of $2.2 million, costs of $1.4 million related to a reduction in our workforce, and a gain on debt extinguishment of $10.6 million. Excluding the unrealized loss on commodity derivatives, impairment expense, rig termination fees, workforce reduction related costs and gain on debt extinguishment, adjusted net loss (non-GAAP) for 2015 was $15.0 million, or $0.37 per diluted share. EBITDAX (non-GAAP) for 2015 was $123.6 million, or $3.05 per diluted share.

Approach Resources, Inc. (NASDAQ:AREX) belongs to Basic Materials sector. Its net profit margin is -87.90% and weekly performance is 115.49%. On last trading day company shares ended up at $1.53.

On 3 March, The Buckle, Inc. (NYSE:BKE) announced that comparable store net sales, for stores open at least one year, for the 4-week period ended February 27, 2016 decreased 8.9 percent from comparable store net sales for the 4-week period ended February 28, 2015. Net sales for the 4-week fiscal month ended February 27, 2016 decreased 7.7 percent to $81.8 million from net sales of $88.6 million for the prior year 4-week fiscal month ended February 28, 2015.

The Buckle, Inc. (NYSE:BKE) shares increased 0.84% in last trading session and ended the day at $31.23. BKE Gross Margin is 43.20% and its return on assets is 27.30%. The Buckle, Inc. (NYSE:BKE) quarterly performance is 2.41%.

Osiris Therapeutics, Inc. (NASDAQ: OSIR) announced the results of its prospective, multi-center, single-arm clinical trial evaluating the clinical outcomes of Grafix® in patients with complex chronic diabetic foot ulcers with exposed tendon and bone.

On 04 March, Osiris Therapeutics, Inc. (NASDAQ:OSIR) shares decreased -1.49% and was closed at $7.28. OSIR EPS growth in last 5 year was -15.80%. Osiris Therapeutics, Inc. (NASDAQ:OSIR) year to date (YTD) performance is -29.87%.

Destination XL Group, Inc. (NASDAQ: DXLG), announced it will release its fourth quarter and fiscal 2015 financial results before the market opens on Friday, March 18, 2016. President and Chief Executive Officer David Levin and Senior Vice President and Chief Financial Officer Peter Stratton will host a conference call the same morning at 9:00 a.m. ET to discuss the results.

Destination XL Group, Inc. (NASDAQ:DXLG) ended the last trading day at $4.80. Company weekly volatility is calculated as 5.75% and price to cash ratio as 43.54. Destination XL Group, Inc. (NASDAQ:DXLG) showed a weekly performance of 6.90%.

bluebird bio, Inc. (NASDAQ: BLUE) announced that interim data from the ongoing Phase 2/3 Starbeam Study (ALD-102) for the treatment of cerebral adrenoleukodystrophy (CALD) will be presented in an oral presentation during the Clinical Trials plenary session on April 20, 2016 at the American Academy of Neurology (AAN) 2016 Annual Meeting. The meeting is being held April 15 – 21, 2016 in Vancouver, BC, Canada.

bluebird bio, Inc. (NASDAQ:BLUE) shares increased 1.17% in last trading session and ended the day at $54.50. BLUE return on assets is -17.90%. bluebird bio, Inc. (NASDAQ:BLUE) quarterly performance is -32.72%.

Leave a Reply

Your email address will not be published. Required fields are marked *